Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

everolimus

- PMLiVE

Novartis says data backs safety of on-hold intrathecal Zolgensma

Data also demonstrated 'remarkable' efficacy in SMA type 2

Novartis day

Novartis donates malaria drug for COVID-19 clinical trials

Hydroxychloroquine will be evaluated for efficacy against novel coronavirus disease

- PMLiVE

Novartis launches $20m COVID-19 response fund

Financial grants will be issued to most impacted communities

- PMLiVE

NICE looks internally for new chief executive

Deputy chief exec Gillian Leng is set to take the helm

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

Celgene’s Revlimid scores NICE approval in follicular lymphoma

New ‘chemotherapy-free’ treatment for patients with limited options

- PMLiVE

Can protein degraders unlock ‘undruggable’ drug targets?

Exploring a new and exciting area of small-molecule drug discovery

- PMLiVE

Ex-Sandoz exec admits role in generic drug price-fixing plot

Reignites criticism of high drug prices in the US

Novartis day

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD

New drug due for launch in Europe in the second quarter

- PMLiVE

Novartis plans inclisiran trial in the UK

Swiss pharma also officially opens new London headquarters

Novartis day

Novartis pulls ahead of Merck in MET-positive lung cancer race

FDA starts priority review of Swiss pharma's MET inhibitor

- PMLiVE

Novartis faces criticism over Zolgensma ‘health lottery’

SMA Europe deems access programme 'inappropriate'

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links